Stock comparison
IDEXX Laboratories
Tandem Diabetes Care
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
TNDM
Tandem Diabetes Care
Market cap
$1.03B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | TNDM | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 24F | IDXX |
| Benjamin Graham | 80A | 73D | IDXX |
| Philip Fisher | 75B | 30F | IDXX |
| Peter Lynch | 71B | 45D | IDXX |
| Joel Greenblatt | 83C | 0F | IDXX |
| Charlie Munger | 87A | 27F | IDXX |
| Terry Smith | 84A | 22F | IDXX |
Side-by-side metrics
| Metric | IDXX | TNDM |
|---|---|---|
| Market cap | $44.12B | $1.03B |
| P/E (TTM) | 39.0x | - |
| EV/EBIT | 31.6x | - |
| ROIC (TTM) | 40.66% | -8.44% |
| Gross margin | 62.05% | 54.93% |
| Net margin | 24.63% | -9.2% |
| Revenue CAGR 5y | 7.56% | 9.62% |
| EPS CAGR 5y | 10.79% | - |
| Debt / Equity | 0.7x | 5.5x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Net margin24.63%vs -9.2%+137%
- ROIC (TTM)40.66%vs -8.44%+121%
- Market cap$44.12Bvs $1.03B+98%
- Debt / Equity0.7xvs 5.5x+88%
TNDM leads on
- EV/EBIT-vs 31.6x+163%
- P/E (TTM)-vs 39.0x+127%
- Revenue CAGR 5y9.62%vs 7.56%+21%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.